
ExpreS2ion announces completion of GLP safety study for ES2B-C001 (HER2-VLP) breast cancer vaccine candidate 16 April 2024
Hørsholm, Denmark, 16 April 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies... Read more
Hørsholm, Denmark, 16 April 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies... Read more
ELEBRATION, Fla., April 15, 2024 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA)... Read more
On 21 March 2024, the company released the great news about the peer-reviewed publication in the journal... Read more
The EU Commision has published the initiative: ”Building the future with nature: Boosting Biotechnology... Read more
First Cannabidiol drug formulation from partnership to enter clinical studies in 2024 February 15, 2024... Read more
Coming Phase I/IIa basket trial planned to include five select cancer indications Study will apply Curasight’s... Read more
Copenhagen, Denmark, 13 February 2024 – Curasight A/S (“Curasight” or the “Company”... Read more
Hørsholm, Denmark, 8 February 2024 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces... Read more
CELEBRATION, Fla., Feb. 06, 2024 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra... Read more